Tse, GaryEmmanuel, BenjaminAriti, ConoBafadhel, MonaPapi, AlbertoCarter, VictoriaZhou, JiandongSkinner, DerekXu, XiaoMüllerová, HanaPrice, David2023-11-152023-11-152023-11-15Tse, G, Emmanuel, B, Ariti, C, Bafadhel, M, Papi, A, Carter, V, Zhou, J, Skinner, D, Xu, X, Müllerová, H & Price, D 2023, 'A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD', International journal of chronic obstructive pulmonary disease , vol. 2023, no. 18, pp. 2565—2580. https://doi.org/10.2147/COPD.S4333261176-9106https://hdl.handle.net/2164/22203Acknowledgments: The authors thank Hilda de Jong, PhD (the PHARMO Institute, Utrecht, the Netherlands) for her assistance in developing the study protocol. The authors also thank Sharen Lee (Cardiovascular Analytics Group, Hong Kong) for her technical assistance in generating the figures for the dose-dependent relationship between OCS dose and adverse outcomes. The authors also thank Colin Bonner, Linda Stotsky, Mario Marinazzo, and Philomena Britto, for their review of the plain language summary as people living with COPD; these individuals were compensated for their time. Medical writing support, under the guidance of the authors, was provided by Sara Cameron, MPhil, and Sarah Piggott, MChem, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca, in accordance with Good Publication Practice (GPP 2022) guidelines. Funding: This study was sponsored by AstraZeneca. All authors, including those employed by the funder of the study, were involved in the interpretation of data, and writing or revising the report, had final responsibility for the decision to submit for publication, and take responsibility for the integrity of the data and the accuracy of the data analysis.166781784engSDG 3 - Good Health and Well-beingchronic obstructive pulmonary diseasecohort studyCOPDcorticosteroidsobservationalPrimary CareR MedicineSupplementary InformationRJournal article10.2147/COPD.S43332618